250 related articles for article (PubMed ID: 17611666)
1. Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions.
Di Carlo A; Mariano A; Terracciano D; Mazzarella C; Galzerano S; Cicalese M; Cecere C; Macchia V
Oncol Rep; 2007 Aug; 18(2):425-31. PubMed ID: 17611666
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Int J Oncol; 2005 May; 26(5):1363-8. PubMed ID: 15809729
[TBL] [Abstract][Full Text] [Related]
3. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
4. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
Swellam M; Arab LR; Bushnak HA
IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
[TBL] [Abstract][Full Text] [Related]
6. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
van Hensbergen Y; Broxterman HJ; Hanemaaijer R; Jorna AS; van Lent NA; Verheul HM; Pinedo HM; Hoekman K
Clin Cancer Res; 2002 Dec; 8(12):3747-54. PubMed ID: 12473585
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer.
Park KJ; Hwang SC; Sheen SS; Oh YJ; Han JH; Lee KB
Respiration; 2005; 72(2):166-75. PubMed ID: 15824527
[TBL] [Abstract][Full Text] [Related]
8. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Kohn EC; Travers LA; Kassis J; Broome U; Klominek J
Diagn Cytopathol; 2005 Nov; 33(5):300-8. PubMed ID: 16240400
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
10. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of angiostatin in effusions from patients with malignant disease.
Rotenberg RG; Rozas NS; Guerri L; Cher ML; Gamboni M; Lema N; Bonfil RD
Oncol Rep; 2004 Feb; 11(2):523-8. PubMed ID: 14719094
[TBL] [Abstract][Full Text] [Related]
12. Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity.
Qu X; Yuan Y; Xu W; Chen M; Cui S; Meng H; Li Y; Makuuchi M; Nakata M; Tang W
Anticancer Res; 2006; 26(5A):3573-8. PubMed ID: 17094485
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis.
Hung TL; Chen FF; Liu JM; Lai WW; Hsiao AL; Huang WT; Chen HH; Su WC
Clin Cancer Res; 2003 Jul; 9(7):2605-12. PubMed ID: 12855637
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer.
Okada N; Ishida H; Murata N; Hashimoto D; Seyama Y; Kubota S
Biochem Biophys Res Commun; 2001 Oct; 288(1):212-6. PubMed ID: 11594775
[TBL] [Abstract][Full Text] [Related]
15. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
Porcel JM; Salud A; Vives M; Esquerda A; Rodríguez-Panadero F
Clin Biochem; 2005 Nov; 38(11):1031-3. PubMed ID: 15925354
[TBL] [Abstract][Full Text] [Related]
16. MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: analysis of MMP-2 and MMP-9 with gelatin zymography.
Iijima T; Minami Y; Nakamura N; Onizuka M; Morishita Y; Inadome Y; Noguchi M
Pathol Int; 2004 May; 54(5):295-301. PubMed ID: 15086833
[TBL] [Abstract][Full Text] [Related]
17. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation.
Sheen P; O'Kane CM; Chaudhary K; Tovar M; Santillan C; Sosa J; Caviedes L; Gilman RH; Stamp G; Friedland JS
Eur Respir J; 2009 Jan; 33(1):134-41. PubMed ID: 18715875
[TBL] [Abstract][Full Text] [Related]
18. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
19. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer.
Patel BP; Shah SV; Shukla SN; Shah PM; Patel PS
Head Neck; 2007 Jun; 29(6):564-72. PubMed ID: 17252594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
